Business Context and Reporting Period
This Form 8-K Current Report was filed by CareDx, Inc. (CDNA) on March 28, 2025. The report discloses a corporate governance event involving the Company's Chief Financial Officer, Abhishek Jain, specifically the execution of an Amended and Restated Change of Control and Severance Agreement dated March 27, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial performance data.
Material Changes
The material change disclosed is the amendment of the severance and change of control agreement for the Chief Financial Officer. The new agreement outlines specific financial entitlements for Mr. Jain in the event of termination without Cause or resignation for Good Reason, both within and outside of a defined "Change of Control Period."
Management Commentary and Contingencies
- Change of Control Period Entitlements: If termination occurs within three months prior to or twelve months following a change of control, Mr. Jain is entitled to:
- A lump sum payment equal to 12 months of annual base salary.
- Acceleration of vesting for 100% of unvested equity awards (performance criteria deemed achieved at target).
- A lump sum payment equal to 100% of the annual bonus.
- Reimbursement of COBRA premiums for 12 months.
- Standard Termination Entitlements: If termination occurs outside the Change of Control Period, Mr. Jain is entitled to:
- 12 months of severance based on annual base salary.
- Reimbursement of COBRA premiums for 12 months.
- Conditions: All payments are conditioned upon the execution of a separation agreement and release of claims in favor of the Company.
Investor Verification Checklist
- Review the full text of the Change of Control and Severance Agreement filed as Exhibit 10.1 to understand specific definitions of "Cause," "Good Reason," and "Change of Control."
- Verify the current annual base salary and target bonus for the CFO to estimate potential liability exposure.
- Assess the impact of the 100% equity vesting acceleration on the Company's future dilution and compensation expense.
- Confirm whether this agreement aligns with the Company's broader executive compensation philosophy and shareholder interests.